PKO Investment Management Joint Stock Co Sells 5,000 Shares of Viking Therapeutics, Inc. $VKTX

PKO Investment Management Joint Stock Co cut its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 33.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,000 shares of the biotechnology company’s stock after selling 5,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Viking Therapeutics were worth $265,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quarry LP boosted its position in shares of Viking Therapeutics by 1,621.4% in the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,135 shares during the period. Parallel Advisors LLC boosted its holdings in Viking Therapeutics by 33.4% in the 2nd quarter. Parallel Advisors LLC now owns 1,818 shares of the biotechnology company’s stock worth $48,000 after buying an additional 455 shares during the period. Farther Finance Advisors LLC increased its stake in Viking Therapeutics by 571.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,041 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,737 shares in the last quarter. Flaharty Asset Management LLC bought a new stake in Viking Therapeutics during the first quarter valued at about $56,000. Finally, JNBA Financial Advisors purchased a new position in shares of Viking Therapeutics in the first quarter valued at about $56,000. Institutional investors own 76.03% of the company’s stock.

Viking Therapeutics Stock Up 1.5%

Viking Therapeutics stock opened at $34.42 on Friday. The company has a market cap of $3.87 billion, a price-to-earnings ratio of -16.24 and a beta of 0.64. The firm’s fifty day moving average is $28.57 and its 200 day moving average is $28.79. Viking Therapeutics, Inc. has a 52-week low of $18.92 and a 52-week high of $81.73.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, October 22nd. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). During the same period last year, the firm earned ($0.22) EPS. Viking Therapeutics’s revenue was up .0% compared to the same quarter last year. On average, equities research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Morgan Stanley lifted their target price on Viking Therapeutics from $98.00 to $102.00 and gave the company an “overweight” rating in a research note on Thursday. B. Riley upgraded shares of Viking Therapeutics to a “strong-buy” rating in a research report on Thursday. Raymond James Financial dropped their target price on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a research report on Thursday, July 24th. Cantor Fitzgerald set a $105.00 price target on shares of Viking Therapeutics in a report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $102.00 price objective on shares of Viking Therapeutics in a report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.62.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.